Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valbenazine for Dyskinesia Due to Cerebral Palsy
NCT05206513Phase 3Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Apr 2022
- Primary completion
- Oct 2025
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of valbenazine in dyskinesia, sponsored by Neurocrine Biosciences. Started Apr 2022; status: completed.
02
Drugs
valbenazine
03
Conditions
dyskinesia
Beyond the preview
Go deeper on NCT05206513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05206513.